Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to initiate a Phase 2 clinical trial of TNX-2900, a proprietary magnesium-potentiated intranasal oxytocin formulation for the treatment of Prader-Willi syndrome (PWS). PWS is a rare genetic disorder and the leading genetic cause of life-threatening childhood obesity. The program has received both Orphan Drug and Rare Pediatric Disease designations from the FDA, making Tonix eligible to receive a transferable Priority Review Voucher upon potential approval of TNX-2900.
The Phase 2 trial will evaluate the safety, tolerability, and efficacy of TNX-2900 in patients with PWS. The company noted that there are currently no FDA-approved treatments for the hyperphagia (excessive hunger) and other behavioral symptoms associated with PWS. TNX-2900 is designed to leverage the synergistic effects of magnesium and oxytocin to enhance central nervous system delivery and activity.
Tonix Pharmaceuticals is a commercial-stage biotechnology company with a diversified pipeline. The company recently received FDA approval for Tonmya, a first-in-class, non-opioid analgesic for fibromyalgia, marking the first new prescription medicine for that condition in over 15 years. Tonix also markets two treatments for acute migraine in adults. Its development portfolio spans central nervous system disorders, immunology, immuno-oncology, and infectious diseases.
In the CNS space, TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study, funded by the U.S. Department of Defense. The immunology portfolio includes TNX-1500, an Fc-modified humanized monoclonal antibody targeting CD40-ligand, being developed to prevent allograft rejection and treat autoimmune diseases. Tonix's infectious disease candidates include TNX-801, a vaccine for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent targeting CD45 under a contract with the U.S. DoD's Defense Threat Reduction Agency for up to $34 million over five years.
The advancement of TNX-2900 underscores Tonix's commitment to addressing unmet medical needs in rare diseases. If successful, the therapy could provide a meaningful treatment option for patients with PWS and their families. The Rare Pediatric Disease designation highlights the potential for TNX-2900 to address a serious or life-threatening condition affecting children, and the Priority Review Voucher program incentivizes the development of such therapies.
More information about Tonix Pharmaceuticals and its pipeline can be found at www.tonixpharma.com. For the latest news on TNXP, visit the company's newsroom at https://ibn.fm/TNXP.
